July 6, 2020
Heta compiler has been published on GitHub as an OpenSource
(Moscow-06.07.2020) InSysBio, one of the world’s pioneers of Quantitative Systems Pharmacology (QSP) modeling, presents Heta compiler which is a tool for the development of Quantitative Systems Pharmacology and Systems Biology platforms. Particularly, it allows combining modules written in different formats like: Heta language code, Excel sheets, JSON, YAML formatted structures, SBML and transforming them into the dynamic models of different formats.
It should be outlined, that Quantitative Systems Pharmacology (QSP) is a discipline that uses mathematical computer models to characterize biological systems, to determine the optimal doses, target groups of patients and substances effect on the human body. QSP typically functions through mechanism-based dynamical models described by ODE systems. Therefore, the modeling systems may include hundreds or thousands of components and are developed by a research group involving people with different expertise. Evgeny Metelkin, Head of InSysBio product development, highlights: “Heta compiler can be used as the framework for a QSP modeling project of any size and complexity. It can be easily integrated with existed infrastructure, workflows or used as a part of the CI/CD strategy”.
Actually, Heta compiler is a tool that allows to perform a number of functions, namely:
Heta compiler is developed as Free Open Source project published on GitHub. The actual version of Heta compiler is 0.5.3, which supports Heta language of version 0.3.1.
Heta compiler is written in JаvaScript/Node language and is distributed as a npm package. This software can work in command line tool mode or may be used as a package for browser or server-side tools and applications.
Heta compiler has already supported the fulfillment of a number of InSysBio projects, namely:
About InSysBio
InSysBio is a Quantitative Systems Pharmacology (QSP) company located in Moscow, Russia (INSYSBIO LLC) and Edinburgh, UK (INSYSBIO UK LIMITED). InSysBio was founded in 2004 and has an extensive track record of helping pharmaceutical companies to make right decisions on the critical stages of drug research and development by application of QSP modeling. InSysBio’s innovative QSP approach has already become a part of the drug development process implemented by our strategic partners: there are more than 100 completed projects in collaboration with leaders of pharmaceutical industry. For more information about InSysBio, its solutions and services, visit www.insysbio.com.
← | September 2024 | → | ||||
Mo | Tu | We | Th | Fr | Sa | Su |
---|---|---|---|---|---|---|
1
| ||||||
2
|
3
|
4
1.
04 Sep 2024 16:07
Now B cells model reflects the current views on the processes
InSysBio launches Immune Response Template (IRT) version 3.6.3. IRT represents a QSP platform of immune system, simultaneously, being a tool for development of models related to immune system
|
5
|
6
|
7
|
8
|
9
|
10
1.
10 Sep 2024 18:36
InSysBio team to publish the new article in PSPJournal
The new article "Quantitative systems pharmacology model of α-synuclein pathology in Parkinson's disease-like mouse for investigation of passive immunotherapy mechanisms" by Olga Ivanova and Tatiana Karelina was published in PSPJournal at the end of August 2024
|
11
1.
11 Sep 2024 15:25
InSysBio to take part in ACoP 2024
InSysBio announces its participation in the 15th American Conference on Pharmacometrics (ACoP). Oleg Demin Jr, Scientific Director, Oncology & Immuno-Oncology, will be a co-chair and speaker of the session "Advancing QSP: From Virtual Patient To Digital Twin". InSysBio team is going to present its modeling services & software to optimize drug development at the Booth #11 and 9 posters in frames of the Conference
|
12
|
13
|
14
|
15
|
16
|
17
|
18
|
19
|
20
|
21
|
22
|
23
|
24
|
25
|
26
|
27
|
28
|
29
|
30
|